Impact of Symprove in irritable bowel syndrome
Research type
Research Study
Full title
A prospective, single-arm, decentralised, real-world evidence pilot study to assess the impact of Symprove in irritable bowel syndrome (IBS)
IRAS ID
353868
Contact name
Alison Clark
Contact email
Sponsor organisation
Symprove Ltd
Duration of Study in the UK
0 years, 4 months, 17 days
Research summary
Irritable Bowel Syndrome (IBS) is a common disorder that affects the digestive system. It's characterised by a range of symptoms including abdominal pain, bloating, gas, and changes in bowel habits. It is well understood that there is overlap between IBS and mental health issues, such as anxiety and depression.
Probiotics and other food supplements can help relieve IBS symptoms in some patients. Symprove is a water-based food supplement containing 4 bacterial strains, which can help stimulate the good bacteria already in the gut. It is already widely available to consumers online and in retail. Symprove has been shown to significantly improve IBS symptoms in previous studies. However, these studies did not assess the impact on mental health.
The aim of our pilot study is to explore the impact of a gut supplement called Symprove on both gut
symptoms and mental health symptoms. We will recruit 150 participants through a single site in the UK. This is a non-randomised virtual study, which does not involve any study visits. After providing consent to take part using an online consent form, all participants will receive a 12-week course of Symprove to take once a day.
Participants will also receive a link to complete an online study survey about their symptoms at the beginning of the study before starting Symprove (Baseline), and at weeks 4, 8 and 12 (follow-up). To assess the impact of Symprove, we will compare the follow-up data to Baseline.The study is sponsored and organized by Symprove Ltd.
REC name
Wales REC 7
REC reference
25/WA/0212
Date of REC Opinion
19 Aug 2025
REC opinion
Further Information Favourable Opinion